Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Mast Therapeutics Inc. (NYSE-M:MSTX) raised $25 million through the sale
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury